ClinicalTrials.gg
CompletedNCT01118325Updated Jul 8, 2014Results posted

An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

A Phase 2 interventional study of ticagrelor and clopidogrel in Stable Coronary Artery Disease, sponsored by AstraZeneca. Completed at 14 sites in 2 countries. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.

Enrollment
24th of 78
146 · median 80
Started
2010
the only one that year
Phase 2
7 of 78
none open now
Registered
5th of 78
by date
Lead sponsor
9 of 78
AstraZeneca

Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 24th largest by enrollment, is the only one that started in 2010, is one of 7 in phase 2, and was the 5th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing ticagrelor in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.

03

Conditions studied

  • Stable Coronary Artery Disease

Keywords

  • Stable Coronary Artery Disease
  • Platelet Aggregation
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any Percutaneous Coronary Intervention, more than 3 months prior to randomization
  • Previous documented acute coronary syndrome (ACS), more than 3 months prior to randomisation
  • Treatment with ASA

Exclusion criteria

Exclusion Criteria:

  • ACS, (TIA), or Stroke within the 3 months prior to randomisation
  • Known concurrent disease of stroke or TIA with atrial fibrillation
  • Persons who are being treated with blood clotting agents that cannot be stopped
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    AZD6140 45 mg bd

    Drug: ticagrelor

  • Experimental
    AZD6140 90 mg bd

    Drug: ticagrelor

  • Active comparator
    Clopidogrel 75 mg od

    Drug: clopidogrel

Interventions

06

What researchers measure

Primary outcomes

  1. Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients

    Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

    Time frame: Week 4

  2. IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients

    Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

    Time frame: Week 4

  3. IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients

    Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

    Time frame: Week 4

  4. IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients

    Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

    Time frame: Week 4

  5. IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients

    Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

    Time frame: Week 4

Secondary outcomes

  1. AZD6140 (Cmax) at Week 4

    Maximum plasma AZD6140 concentration

    Time frame: Week 4

  2. AZD6140 (AUC0-tau) at Week 4

    Area under the plasma concentration curve of AZD6140 from time zero to dosing interval

    Time frame: Week 4

  3. AZD6140 (Tmax) at Week 4

    Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration

    Time frame: Week 4

  4. AR-C124910XX (Cmax) at Week 4

    Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX

    Time frame: Week 4

  5. AR-C124910XX (AUC0-tau) at Week 4

    Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval

    Time frame: Week 4

  6. AR-C124910XX (Tmax) at Week 4

    Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration

    Time frame: Week 4

07

Results

Posted Apr 9, 2012

Participant flow

In total, 146 patients were enrolled at 15 sites from 2 countries (Japan and Philippines). The study period was from April 2010 to March 2011. In total, 139 subjects were randomised and received the investigational product. Most subjects completed the study but 2 Japanese patients discontinued due to an AE during the 4 weeks treatment period.

Participant flow — Overall Study
MilestoneAZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
Started504346
Completed494345
Not completed101
Withdrew: Adverse event101

Outcome measures

PrimaryInhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients

Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

Time frame:
Week 4
Reported as:
Mean · percentage inhibition
Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients
percentage inhibitionAZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients64.5 ± 14.873.0 ± 14.238.9 ± 20.7
PrimaryIPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients

Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

Time frame:
Week 4
Reported as:
Mean · percentage inhibition
IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients
percentage inhibitionAZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients67.3 ± 15.673.2 ± 15.143.7 ± 20.6
PrimaryIPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients

Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

Time frame:
Week 4
Reported as:
Mean · percentage inhibition
IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients
percentage inhibitionAZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients62.7 ± 17.768.6 ± 16.042.5 ± 20.2
PrimaryIPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients

Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

Time frame:
Week 4
Reported as:
Mean · percentage inhibition
IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients
percentage inhibitionArm 1 - AZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients56.9 ± 20.966.8 ± 20.141.8 ± 21.7
PrimaryIPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients

Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation: Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval \[0,100\]; any data falling outside this range was truncated to the appropriate limit.

Time frame:
Week 4
Reported as:
Mean · percentage inhibition
IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients
percentage inhibitionAZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients46.2 ± 23.359.1 ± 20.338.0 ± 20.5
SecondaryAZD6140 (Cmax) at Week 4

Maximum plasma AZD6140 concentration

Time frame:
Week 4
Reported as:
Geometric mean · ng/mL
AZD6140 (Cmax) at Week 4
ng/mLAZD6140 45 mg bd in Japanese PatientsAZD6140 45 mg bd in Non-Japanese PatientsAZD6140 90 mg bd in Japanese PatientsAZD6140 90 mg bd in Non-Japanese Patients
AZD6140 (Cmax) at Week 4422 ± 230341 ± 370931 ± 4421380 ± 343
SecondaryAZD6140 (AUC0-tau) at Week 4

Area under the plasma concentration curve of AZD6140 from time zero to dosing interval

Time frame:
Week 4
Reported as:
Geometric mean · ng.h/mL
AZD6140 (AUC0-tau) at Week 4
ng.h/mLAZD6140 45 mg bd in Japanese PatientsAZD6140 45 mg bd in Non-Japanese PatientsAZD6140 90 mg bd in Japanese PatientsAZD6140 90 mg bd in Non-Japanese Patients
AZD6140 (AUC0-tau) at Week 43050 ± 19402930 ± 37406080 ± 260010900 ± 2790
SecondaryAZD6140 (Tmax) at Week 4

Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration

Time frame:
Week 4
Reported as:
Median · hour
AZD6140 (Tmax) at Week 4
hourAZD6140 45 mg bd in Japanese PatientsAZD6140 45 mg bd in Non-Japanese PatientsAZD6140 90 mg bd in Japanese PatientsAZD6140 90 mg bd in Non-Japanese Patients
AZD6140 (Tmax) at Week 42.0 (1.9 to 4.0)4.0 (2.0 to 4.0)2.0 (1.9 to 4.1)4.0 (2.0 to 4.1)
SecondaryAR-C124910XX (Cmax) at Week 4

Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX

Time frame:
Week 4
Reported as:
Geometric mean · ng/mL
AR-C124910XX (Cmax) at Week 4
ng/mLAZD6140 45 mg bd in Japanese PatientsAZD6140 45mg bd in Non-Jpanese PatientsAZD6140 90 mg bd in Japanese PatientsAZD6140 90 mg bd in Non-Jpanese Patients
AR-C124910XX (Cmax) at Week 4135 ± 53.3101 ± 72.4326 ± 139381 ± 192
SecondaryAR-C124910XX (AUC0-tau) at Week 4

Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval

Time frame:
Week 4
Reported as:
Geometric mean · ng.h/mL
AR-C124910XX (AUC0-tau) at Week 4
ng.h/mLAZD6140 45 mg bd in Japanese PatientsAZD6140 45 mg bd in Non-Japanese PatientsAZD6140 90 mg bd in Japanese PatientsAZD6140 90 mg bd in Non-Japanese Patients
AR-C124910XX (AUC0-tau) at Week 41180 ± 490954 ± 7412720 ± 9153380 ± 1580
SecondaryAR-C124910XX (Tmax) at Week 4

Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration

Time frame:
Week 4
Reported as:
Median · hour
AR-C124910XX (Tmax) at Week 4
hourAZD6140 45 mg bd in Japanese PatientsAZD6140 45 mg bd in Non-Japanese PatientsAZD6140 90 mg bd in Japanese PatientsAZD6140 90 mg bd in Non-Japanese Patients
AR-C124910XX (Tmax) at Week 44.0 (1.9 to 11.9)4.0 (2.0 to 8.0)2.1 (1.9 to 8.0)2.0 (2.0 to 4.0)

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD6140 45 mg bd—2/50 (4%)13/50 (26%)
AZD6140 90 mg bd—1/43 (2.3%)23/43 (53.5%)
Clopidogrel 75 mg od—0/46 (0%)9/46 (19.6%)
Most frequent serious events
Most frequent serious events
EventAZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
LIP AND/OR ORAL CAVITYCANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/501/430/46
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/500/430/46
PNEUMONIARespiratory, thoracic and mediastinal disorders1/500/430/46
Most frequent other events
Most frequent other events
EventAZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg od
Haemorrhage subcutaneousSkin and subcutaneous tissue disorders9/509/433/46
NasopharyngitisInfections and infestations1/507/433/46
Abdominal discomfortGastrointestinal disorders2/502/432/46
ConstipationGastrointestinal disorders0/502/430/46
Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders0/502/430/46
ArthralgiaMusculoskeletal and connective tissue disorders0/502/430/46
EpistaxisRespiratory, thoracic and mediastinal disorders1/501/432/46
HeadacheNervous system disorders2/501/430/46

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg odTotal
Mean63 ± 1164 ± 964 ± 1063 ± 10
Sex: Female, Male
Sex: Female, Male(Participants)AZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg odTotal
Female43815
Male464038124
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD6140 45 mg bdAZD6140 90 mg bdClopidogrel 75 mg odTotal
Japanese423540117
Non-Japanese88622
08

Study locations

14 sites
  • Research Site
    Mizumaki, Fukuoka, Japan
  • Research Site
    Sapporo-shi, Hokkaido, Japan
  • Research Site
    Toride-shi, Ibaraki, Japan
  • Research Site
    Kawasaki-shi, Kanagawa, Japan
  • Research Site
    Kyoto-shi, Kyoto, Japan
  • Research Site
    Naha-shi, Okinawa, Japan
  • Research Site
    Osaka-shi, Osaka, Japan
  • Research Site
    Kusatsu-shi, Shiga, Japan
  • Research Site
    Komatsushima-shi, Tokushima, Japan
  • Research Site
    Shinagawa-ku, Tokyo, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Davao City, Philippines
  • Research Site
    Quezon City, Philippines
09

References and documents

Publications

  • Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014 Oct;29(4):324-33. doi: 10.1007/s12928-014-0277-1. Epub 2014 Jun 17. PubMed 24935072 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 1 year 1 month after primary completion. A results delay was requested in Feb 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2010
First posted
May 6, 2010
Start
Apr 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results delay requested
Feb 23, 2011
Results first posted
Apr 9, 2012
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01118325
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 6, 2010
Start date
Apr 2010
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Apr 9, 2012
Last update
Jul 8, 2014

Study contacts

Jonathan C. Fox, MD
study director · AstraZeneca

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion